Thumbnail

Covid-19 complicated by high Venous Thromboembolism (VTE) and bleed risk in critically ill patients.

  • Study reports abnormally high VTE and high bleed risk in critically ill Covid-19 patients and calls for more effective prevention strategies.
  • Clinicians at NHS hospitals are supporting the care of Covid-19 patients with the use of geko™ devices to reduce the risk of blood clots in the most at risk patients.
 Learn more Contact us

Partner with us!

We are committed to partnering with healthcare professionals to solve challenging medical problems

Current research opportunities – 2023:  

We have particular interest in the following clinical application areas, and are seeking to partner with clinicians willing to investigate:

Use of the geko™ for the reduction of post-operative oedema reduction in:

  • Total knee replacement surgery
  • Partial or total hip replacement surgery
  • Anterior Cruciate Ligament (ACL) surgery

To register your interest, please compete our on-line form below. Our therapy area director will contact you.

Fresh idea!

We welcome an active exchange of ideas to address clinical challenges in areas of unmet need where the geko™ device might provide the answer. If you have a research idea or proposal you would like to discuss, we invite you to submit your idea, and the therapeutic area, using our on-line form below.

The support we provide may take the form of product or funding, dependent on the type of research and availability of funds. We also provide technical and/or protocol development support, as allowed under local laws and regulations, and provided the research is aligned to our company defined areas of strategic interest.

The types of eligible research we support include:

  1. On-label studies aligned to business strategy and regulatory compliance.
  2. Observational, non-interventional patient tolerance evaluations (product evaluations)
  3. Prospective and retrospective studies (clinical audits)
  4. Studies having reasonable sample size and follow-up timelines.
  5. Studies having budgets that are of fair market value.
  6. Studies subject to a well-designed written protocols, operational expertise and expert statistical support.
  7. Studies that provide updates, a final written report, publishable results, and a commitment to present findings at congress.

As well as collaborative research, to identify new therapeutic applications, we welcome contact from organisations interested to discuss licencing our platform technology, OnPulse™. Please email Andrew Thelwell, CCO Firstkind Ltd, on: geko.support@firstkindmedical.com

    Physician’s Information

    Location Information